Share This Page
Drugs in ATC Class A16AX
✉ Email this page to a colleague
Drugs in ATC Class: A16AX - Various alimentary tract and metabolism products
| Tradename | Generic Name |
|---|---|
| OLPRUVA | sodium phenylbutyrate |
| PHEBURANE | sodium phenylbutyrate |
| BUPHENYL | sodium phenylbutyrate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class A16AX (Alimentary tract and metabolism products) including key active ingredients, exclusivity timelines, and generic/biosimilar entry risk
ATC Class A16AX is a high-fragmentation segment spanning multiple unrelated “various” alimentary tract and metabolism agents. The patent and market dynamics are therefore ingredient-specific rather than class-wide: each active ingredient has its own FDA status (NDA vs ANDA vs 505(b)(2)), Orange Book listings, patent term, and litigation pattern. A16AX generally does not have a single dominant block of blockbuster revenue with a uniform patent estate. Instead, revenue exposure and generic entry risk come from a set of individually patented drug products within the class.
What patents protect ATC A16AX products, and how strong is the patent estate by active ingredient?
Featured snippet answer: Patent protection for A16AX depends on the specific listed drug product. In practice, protection concentrates in (i) composition-of-matter and polymorph/crystal form patents (where applicable), (ii) formulation patents (controlled release, enteric coatings, combinations), and (iii) method-of-use patents tied to specific indications or patient subpopulations.
Why “A16AX” is not a single patent estate
A16AX is the ATC “Various alimentary tract and metabolism products” bucket. It aggregates products with different mechanisms (enzymes, bile-related agents, metabolic adjuncts, and other GI/metabolism therapies). That makes “class-level” patent forecasting unreliable. For investors and litigators, the correct unit is the branded NDA (or 505(b)(2) product) and its Orange Book patent families.
Patent types that most often drive Orange Book exclusivity in GI/metabolism “various” products
Across A16AX-like segments, the strongest and most litigated rights usually map to:
- Composition-of-matter: active ingredient, salts, solvates, and polymorphs.
- Formulation and delivery systems: granulation/process, coatings, release rate, stabilizers.
- Method of use: specific dosing regimens, duration, responder definitions, or comorbidity-linked indications.
- Manufacturing/process claims: crystallization, drying, and impurity control steps.
Practical strength rating framework for A16AX products
A defensible “strong estate” profile typically shows:
- Multiple, staggered Orange Book-listed patents across distinct claim scopes (composition + formulation + method).
- Independent claim coverage (not all patents share the same specification dependency).
- Patent term extensions or pediatric exclusivity that extends NDA exclusivity end dates.
- A recent litigation/settlement history that indicates non-trivial defense positions (even if outcomes vary).
A “thin estate” profile usually shows:
- Only one or two Orange Book patents, often formulation-only.
- Close timing between key patent expirations and foreseeable ANDA filing windows.
- Prior carve-outs in settlements that shift infringement risk to generic design-arounds.
When does exclusivity end for A16AX drugs, and when can generics file Paragraph IV ANDAs?
Featured snippet answer: Exclusivity end dates and Paragraph IV filing windows are drug-product specific. The earliest safe generic filing point is typically tied to the NDA regulatory exclusivity expiration (NCE/3-year/5-year depending on status) and later any pediatric exclusivity, after which ANDA applicants can file with Paragraph IV certifications against Orange Book patents.
How to translate exclusivity into a generic launch timeline
For A16AX, generic launch timing typically follows:
- NDA exclusivity expires (and any pediatric exclusivity extension ends).
- ANDA filing may occur with Paragraph IV certifications against Orange Book patents listed for the product.
- 30-month stay triggers if a compliant Paragraph IV suit is filed (or if suit is filed within required deadlines).
- Patent expiration or settlement controls market entry date.
Why timing differs even within the same ATC bucket
GI/metabolism products frequently include:
- New chemical entities (NCEs) that carry 5-year exclusivity.
- Line extensions (formulation/dosing changes) with their own exclusivity profiles.
- 505(b)(2) routes that inherit reference listing strategies and may create narrower but still litigated patent coverage.
Which generic challenges are most likely for A16AX, and what Paragraph IV patterns drive settlements?
Featured snippet answer: Likely Paragraph IV challenges come from ANDA applicants targeting formulation or method-of-use patents that appear to be the principal Orange Book hooks. Settlement outcomes are often driven by whether the brand’s patents are older, whether they have remaining term, and whether claim construction and infringement theories are straightforward.
Common Paragraph IV targeting strategy in GI/metabolism
- Formulation patents: challenge via alternative excipient systems, particle size distributions, or coating/release profiles.
- Method-of-use patents: challenge via alternative labeling, dosing, or patient-selection arguments.
- Process patents: challenge via different manufacturing pathways to avoid literal infringement or doctrine-of-equivalents scope.
What to watch in A16AX litigation records
Even without a single class-wide patent landscape, patterns repeat:
- Brand enforcement tends to focus on patents with clear claim-feature mapping to the commercial product.
- Settlements often include:
- Design-around permissions for certain patents.
- Carve-outs by strength or dosage form.
- Agreed launch dates tied to the next unexpired Orange Book patent.
What formulations are protected in A16AX, and where are the most frequent infringement hot spots?
Featured snippet answer: In A16AX, formulation patents and delivery-system claims are often the most contested. Hot spots include release control, coating integrity, impurity profiles, and stability-linked formulation choices.
Dosage-form categories that frequently generate separate IP families
- Oral controlled release (extended/modified release): release kinetics and polymer matrices.
- Enteric coated products: pH-dependent release and coating thickness.
- Granules, pellets, and multiparticulates: size distribution and layering processes.
- Combinations: fixed-dose combinations create multi-layer protection (actives, ratios, and device/formulation).
Infringement and design-around map (how generics attempt to avoid patents)
Typical design-around logic:
- Shift release profile to fall outside a claimed dissolution range.
- Change manufacturing process to avoid a claimed crystallization or drying parameter.
- Modify coating composition or thickness to move outside a defined coating/processing window.
What is the Orange Book status of A16AX drugs, and how many patents cover each product?
Featured snippet answer: Orange Book status is product specific and must be checked at the NDA product level to count listed patents and assess coverage breadth. For A16AX, the number of patents can range from a handful (thin estate) to multiple families spanning composition, formulation, and method claims.
How patent counts typically correlate with litigation intensity
- Fewer than ~5 Orange Book patents: litigation may focus on a single dominant patent or may not justify active defense across multiple claims.
- More than ~8 to 12 Orange Book patents: higher probability that enforcement is multi-front, with structured settlements for phased entry.
Product-level patent families usually fall into these buckets
- Active ingredient or salt/polymorph family.
- Dosage form/formulation family.
- Method-of-use family tied to an indication and label.
- Manufacturing/process family.
How do A16AX drug patent estates compare with each other, and what does that imply for investment risk?
Featured snippet answer: Within A16AX, investment risk clusters by estate breadth and remaining term rather than by the ATC label. Products with stacked composition + formulation + method patents typically show lower generic probability during the remaining term; products with one or two formulation hooks show higher early entry risk.
Comparative risk drivers by “estate architecture”
- Stacked patents with different claim scope (lower risk)
- Generics face multiple infringement theories.
- Settlements often require longer brand protection.
- Single dominant formulation patent (higher risk)
- One successful design-around can unlock market entry.
- Older patents with narrow remaining scope (mixed)
- Even if patents exist, claim scope may be easier to avoid.
- Recent NCE approvals (lower risk short term, watch longer term)
- New exclusivity end dates can delay filings.
What patent expiration dates matter most for generic entry in A16AX?
Featured snippet answer: The most material dates for entry are:
- the last Orange Book patent expiration (including any non-patent exclusivities),
- any pediatric exclusivity end date,
- and the likely settlement-controlled launch date (often earlier than the last patent expiration only if the settlement authorizes entry against remaining patents).
Expiration date hierarchy to build an entry calendar
- NDA regulatory exclusivity end (NCE/5-year, 3-year, 505(b)(2) exclusivity mechanics).
- Patent term (utility) and any Patent Term Extension (PTE).
- Pediatric exclusivity (6-month extension).
- Orange Book patent-specific expiration for ANDA certification strategy.
What biosimilar risks exist for A16AX?
Featured snippet answer: Biosimilar risk is generally low for A16AX because the segment is typically dominated by small molecules and GI/metabolism adjuncts rather than biologics. If an A16AX-listed product is a biologic, the biosimilar risk assessment would be ingredient- and product-specific based on FDA reference product, licensure date, and biologics exclusivity periods.
Practical consequence for A16AX diligence
Biosimilar analysis should be triggered only if the A16AX product is a biologic with FDA licensure and reference product data.
Which companies are challenging A16AX patents, and how do settlements shape market entry?
Featured snippet answer: Challenge filers and settlement parties are product-specific and should be read from FDA ANDA filing certifications and court dockets for each branded product. In A16AX, settlement structures typically follow:
- staged entry by strength/dosage form,
- agreed-date entry aligned to the “next expiring” Orange Book patent,
- and non-waiver language tied to remaining patents.
How to interpret settlements in A16AX
Settlement agreements drive the “real-world” entry date even when patent expirations suggest a different calendar. The key business signal is whether the settlement grants entry:
- immediately after one key patent expiration, or
- only after multiple patents expire, or
- with carve-outs limited to certain strengths/labels.
What FDA status drives market dynamics for A16AX: NDA, ANDA, or 505(b)(2)?
Featured snippet answer: FDA pathway determines the competitive filing cadence. NDAs govern initial exclusivity; ANDAs drive generic entry; 505(b)(2) often produces narrower label changes that still compete directly.
Diligence map for A16AX competitiveness
- NDA with narrow label: may discourage generic entrants if method-of-use coverage is hard to certify.
- NDA with broad label: encourages multiple ANDA filers.
- 505(b)(2) dependence: can add patent-listed reference product hooks and delay generic entry if patent coverage inherits key elements.
What is the competitive landscape for A16AX, and how concentrated is the branded base?
Featured snippet answer: A16AX competition is usually characterized by fragmented branded ownership across multiple agents rather than one concentrated “platform brand.” Concentration varies by region and by whether a product is a dominant GI/metabolism therapy or an adjunct with smaller revenue.
Market dynamic drivers that repeatedly matter in A16AX
- reimbursement positioning for GI/metabolism disorders,
- label scope and clinical differentiation,
- payer step edits and prior authorization,
- safety/tolerability perception (which can influence generic substitution speed),
- and the breadth of Orange Book coverage affecting time-to-entry.
Key Takeaways
- A16AX is a mixed “various” bucket. The patent landscape is ingredient-by-ingredient and product-by-product, not class-wide.
- Generic entry timing is governed by NDA exclusivity end dates plus the last Orange Book patent expiration that supports enforceable certification and any 30-month ANDA stay or settlement launch date.
- The most frequent patent infringement hot spots in GI/metabolism products are formulation/delivery system claims and method-of-use claims tied to labeling and dosing.
- Investment and litigation risk in A16AX correlates with estate architecture: stacked composition/formulation/method patents reduce near-term generic probability; thin estates with a single dominant formulation hook raise early entry risk.
- Biosimilar risk is typically low for A16AX unless a specific A16AX-listed product is biologic.
FAQs
- How do I estimate generic launch date for an A16AX product if I know only its Orange Book patent expiration?
- Which Orange Book patent types (composition vs formulation vs method) most often survive Paragraph IV challenges in GI/metabolism products?
- What settlement terms most commonly delay or accelerate entry for ANDA filers targeting A16AX brands?
- When does a 505(b)(2) A16AX product create unique patent barriers compared with an NDA?
- How should I rank A16AX products by patent-risk using only public litigation dockets and FDA listings?
References
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database).
- U.S. FDA. Drug Approval Reports and Drug Products Databases (NDA/ANDA/505(b)(2) records). (FDA databases).
- U.S. FDA. Exclusivity and Patent Certifications under the Hatch-Waxman Amendments (FDA guidance and reference materials). (FDA guidance).
More… ↓
